Edward J III Dulac Insider Profile

4 Followers
Edward J III Dulac, CFO at Fate Therapeutics, holds 66.32K shares in Intellia Therapeutics (Ticker: NTLA), holds 101.48K shares in Fate Therapeutics (Ticker: FATE).
tipranks
Edward J III Dulac

Edward J III Dulac
Fate Therapeutics (FATE)
CFO

Ranked #6,355 out of 99,335 Corporate Insiders

Profitable Transactions

83%
5 out of 6 Profitable Transactions

Average Return

+43.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$1M
81.71%
18.29%
A breakdown of Edward J III Dulac's holdings

Insider Roles

Intellia Therapeutics
(NTLA)
EVP, Chief Financial Officer
Fate Therapeutics
(FATE)
CFO
Roles that Edward J III Dulac holds in companies

Most Profitable Insider Trade

Stock:
Fate Therapeutics
(FATE)
Rating:Informative Sell
Date:Aug 19, 2022 - Aug 19, 2023
Return:+90.40%
The most profitable trade made by Edward J III Dulac

Edward J III Dulac's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Fate Therapeutics
Mar 05, 2024
CFO
Uninformative Sell
19.01K
$259.79K
Intellia Therapeutics
Jul 24, 2024
EVP, Chief Financial Officer
Uninformative Buy
$1.16M
List of latest transactions for each holding click on a transaction to see Edward J III Dulac's performance on stock

Edward J III Dulac insider profile FAQ

What is the percentage of profitable transactions made by Edward J III Dulac?
The percentage of profitable transactions made by Edward J III Dulac is 83%.
    What is the average return per transaction made by Edward J III Dulac?
    The average return per transaction made by Edward J III Dulac is 43.30%.
      What stocks does Edward J III Dulac hold?
      Edward J III Dulac holds: FATE, NTLA stocks.
        What was Edward J III Dulac’s latest transaction?
        Edward J III Dulac latest transaction was an Uninformative Buy of ―.
          What was Edward J III Dulac's most profitable transaction?
          Edward J III Dulac’s most profitable transaction was an Informative Sell of FATE stock on August 19, 2022. The return on the trade was 90.40%.
            What is Edward J III Dulac's role in Fate Therapeutics?
            Edward J III Dulac's role in Fate Therapeutics is CFO.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.